Human OPG FlowCytomix Simplex

Description: This FlowCytomix Simplex Kit is designed for the measurement of Human OPG in an immunoassay analyzed on a flow cytometer. Together with the FlowCytomix Human Basic Kit (cat. BMS8420FF), this kit can be used to detect OPG alone or can be multiplexed with other Simplex Kits to measure a variety of analytes.

This kit contains bead population A6.

Osteoprotegerin (OPG) is a member of the TNF receptor family expressed by osteoblasts. OPG has documented effects on the regulation of bone metabolism. It inhibits bone resorption and binds with strong affinity to its ligand RANKL, thereby preventing RANKL from binding its receptor RANK. This system is regulated by calcium-modifying hormones and the humoral factors. Modulation of the RANKL/RANK/OPG system in animal results in a skeletal and vascular phenotype. OPG also has a role in the regulation of the immune response regulating the interactions between T cells and DCs acting as decoy receptor.

A number of clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases have been described, OPG thus playing an important role in obesity.

References: Blair,H.C.; Athanasou,N.A.. Recent advances in osteoclast biology and pathological bone resorption. Histol.Histopathol. 2004;19:189-199. (Link)

Sattler,A.M.; Schoppet,M.; Schaefer,J.R.; Hofbauer,L.C.. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif.Tissue Int. 2004;74:103-106. (Link)

Bengtsson,A.K.; Ryan,E.J.. Immune function of the decoy receptor osteoprotegerin. Crit Rev.Immunol. 2002;22:201-215. (Link)

Hofbauer,L.C.; Schoppet,M.. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-495. (Link)

Roux,S.; Mariette,X.. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. Leuk.Lymphoma 2004;45:1111-1118. (Link)

Aubin,J.E.; Bonnelye,E.. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption 7. Osteoporos.Int. 2000;11:905-913. (Link)

Cheng,X.; Kinosaki,M.; Murali,R.; Greene,M.I.. The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol.Res. 2003;27:287-294. (Link)

Garnero,P.; Delmas,P.D.. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr.Opin.Rheumatol. 2004;16:428-434. (Link)

Salmon,P.. Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone. J.Bone Miner.Res. 2004;19:695-702. (Link)

Takahashi,N.; Udagawa,N.; Suda,T.. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem.Biophys.Res.Commun. 1999;256:449-455. (Link)

Schoppet,M.; Preissner,K.T.; Hofbauer,L.C.. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler.Thromb.Vasc.Biol. 2002;22:549-553. (Link)

Kostenuik,P.J.; Shalhoub,V.. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr.Pharm.Des 2001;7:613-635. (Link)

Wittrant,Y.; Theoleyre,S.; Chipoy,C.; Padrines,M.; Blanchard,F.; Heymann,D.; Redini,F.. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim.Biophys.Acta 2004;1704:49-57. (Link)

Saidenberg,Kermanac'h N.; Bessis,N.; Cohen-Solal,M.; De Vernejoul,M.C.; Boissier,M.C.. Osteoprotegerin and inflammation. Eur.Cytokine Netw. 2002;13:144-153. (Link)

Sezer,O.; Heider,U.; Zavrski,I.; Kuhne,C.A.; Hofbauer,L.C.. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098. (Link)

Barille-Nion,S.; Bataille,R.. New insights in myeloma-induced osteolysis. Leuk.Lymphoma 2003;44:1463-1467. (Link)

Khosla,S.. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055. (Link)

Schett,G.; Redlich,K.; Smolen,J.S.. The role of osteoprotegerin in arthritis. Arthritis Res.Ther. 2003;5:239-245. (Link)

Saidenberg-Kermanac'h,N.; Cohen-Solal,M.; Bessis,N.; De Vernejoul,M.C.; Boissier,M.C.. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 2004;71:9-13. (Link)